February 1, 2017 / 1:23 PM / 3 years ago

BRIEF-Audentes Therapeutics announces FDA clearance of investigational new drug application for AT342

Feb 1 (Reuters) - Audentes Therapeutics Inc

* Audentes Therapeutics announces FDA clearance of investigational new drug application for AT342 to treat Crigler-Najjar Syndrome

* Plans to initiate Valens, multicenter, multinational, open-label, ascending dose phase 1/2 clinical study of AT342

* Preliminary data from Valens is expected to be available by end of 2017

* Plans to imminently begin Lustro, a clinical assessment and run-in study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below